Source: Martin Barraud/Getty Images

10 Countries in 100K Genome Club

These ten governments have committed funding for projects that will sequence a minimum of 100,000 citizens to spur genomic medicine

Former Foundation Medicine Execs Join Hopkins Kimmel Directors, VCs in New Company

Steven Kafka, Ph.D., the former president and chief operating officer of Foundation Medicine who left the company last year, has joined with former colleagues...

Exclusive: A Conversation with David Bentley, VP and Chief Scientist, Illumina

From Guy's Hospital in London and the Sanger Centre during the Human Genome Project to one of the first to join early sequencing company Solexa and its subsequent acquisition by Illumina, David Bentley has seen clinical genomics come full circle.
Adding blood-based liquid biopsy testing nearly doubled the number of mutations detected in non-small cell lung cancer (NSCLC) compared to solid tissue testing alone

Liquid Biopsies Provide Precision Approach to Ovarian Cancer Treatment

Scientists based at the University of Helsinki reported they were able to use the circulating tumor DNA shed by ovarian tumors to identify clinically actionable mutations and provide targeted treatments to patients.
Clinician Offering Drugs Based On DNA Profiling

FDA Sends Warning Letter to Inova Over Pharmacogenomics Test

The agency said it is unaware of data establishing that Inova’s tests helps patients or clinicians make appropriate treatment decisions for the listed drugs.
The American Association of Clinical Urologists (AACU) has issued a position statement encouraging the use of tissue-based molecular testing and/or germline testing for three groups of prostate cancer patients. [Ji-Xin Cheng

Clinical Urologists Group Supports Genomic Testing for Prostate Cancer

AACU statement encourages use of tissue-based molecular testing and/or germline testing for three groups of prostate cancer patients

Proteogenomic Colon Cancer Analysis Offers New Diagnostic, Therapeutic Insights

Colon cancer ranks third in prevalence and fourth in cancer deaths among all cancers worldwide. However, due to its extreme heterogeneity, progress has been slow towards precision diagnostics and treatments.
Whole exome sequencing is becoming more available to patients and will help them distill the sequencing data to candidate genes and link them with therapies. [NCI]

Cancer Combination Therapies Tailored to Individuals Show Improved Outcomes

Patients with therapy-resistant cancers show improved outcomes if their treatments are personalized according to the molecular profile of their cancer, according to a new...

PerkinElmer, Helix Partner to Launch Genetic Screening Test

The DNA test available to healthy individuals analyzes all 59 medically actionable genes identified by the American College of Medical Genetics and Genomics.
3d rendered ovarian cancer illustration.

Genetic Testing for Ovarian Cancer Patients is Underused

Patients with ovarian cancer are not getting all the testing they need, according to study a recently published in Journal of Clinical Oncology. Breast and...
Scroll Up